Pacira Pharmaceuticals Stock News

Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

-- EXPAREL average daily sales for May 2021 were 162% of May 2020 -- -- EXPAREL momentum continues with average daily sales for May 2021 at 105% of April 2021 --

Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor

Pacira BioSciences reported earnings last week, and the company missed on its EPS estimate while beating its revenue estimate.

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q1 2021 Results - Earnings Call Transcript

PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets

-- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industr

Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity Complaint challenges the Am

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

This healthcare stock just got great news from the Food and Drug Administration.

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

-- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over –-- Conference call tomorrow at 8:30 a.m. ET -- PARSIPPANY, N.J., March 22, 2021 (GLOBE NEWSW

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the bigges

-- EXPAREL average daily sales at 103% of the prior year for the month of February 2021 -- PARSIPPANY, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry le